Table 1.
Pathological and clinical data of the arrayed prostate cancers
| No. of patients (%) | ||
|---|---|---|
| Study cohort on TMAa | Biochemical relapse | |
| Follow-up (month) | ||
| N | 11,665 | 2769 (23.7%) |
| Mean / median | 62.9 / 50.0 | – |
| Age (y) | ||
| ≤ 50 | 334 | 81 (24.3%) |
| 51–59 | 3061 | 705 (23.0%) |
| 60–69 | 7188 | 1610 (22.4%) |
| ≥ 70 | 1761 | 370 (21.0%) |
| Pretreatment PSA (ng/ml) | ||
| < 4 | 1585 | 242 (15.3%) |
| 4–10 | 7480 | 1355 (18.1%) |
| 10–20 | 2412 | 737 (30.6%) |
| > 20 | 812 | 397 (48.9%) |
| pT stage (AJCC 2002) | ||
| pT2 | 8187 | 1095 (13.4%) |
| pT3a | 2660 | 817 (30.7%) |
| pT3b-4 | 1528 | 847 (55.4%) |
| Gleason grade | ||
| ≤ 3 + 3 | 2848 | 234 (8.2%) |
| 3 + 4 | 6679 | 1240 (18.6%) |
| 3 + 4 Tertiary 5 | 433 | 115 (26.6%) |
| 4 + 3 | 1210 | 576 (47.6%) |
| 4 + 3 Tertiary 5 | 646 | 317 (49.1%) |
| ≥ 4 + 4 | 596 | 348 (58.4%) |
| pN stage | ||
| pN0 | 6970 | 1636 (23.5%) |
| pN+ | 693 | 393 (56.7%) |
| Surgical margin | ||
| Negative | 9990 | 1848 (18.5%) |
| Positive | 2211 | 853 (38.6%) |
aNumbers do not always add up to 12,427 in different categories because of cases with missing data. Abbreviation: AJCC American Joint Committee on Cancer